Depakote

Basic Depakote information

• INN (international nonproprietary name): valproate semisodium (divalproex sodium)
• Brand names available in the United Kingdom: Depakote; Convulex (valproic acid); generic valproate products
• ATC code: N03AG01
• Forms and strengths: gastro-resistant tablets 250 mg and 500 mg
• Manufacturers in the United Kingdom: Sanofi; generic manufacturers
• Registration status in the United Kingdom: not specified
• OTC / Rx classification: Prescription-only medicine (Rx)

Clinical effectiveness in the UK

Many patients want to know whether Depakote actually works for seizures and mood.

Valproate produces meaningful seizure reduction in many people with generalised epilepsies when plasma levels are maintained.

In acute bipolar mania, valproate semisodium can achieve rapid symptom control, and many patients stabilise on maintenance regimens.

Common problems include weight gain, sedation and cognitive slowing, which can affect employment and driving.

Structured monitoring and pharmacist counselling support adherence.

MHRA and NICE‑aligned pathways require documented pregnancy prevention discussions for women of childbearing potential before valproate treatment is started for any indication.

Indications and expanded uses — MHRA‑approved and off‑label practice

Patients ask: what is Depakote licensed for, and when is it used off‑label?

In the UK, Depakote (valproate semisodium) is licensed for the treatment of manic episodes in bipolar disorder; other valproate products (sodium valproate) are licensed for epilepsy, and migraine prophylaxis is an off-label use.

Standard adult starting doses are: mania around 750 mg/day in divided doses (Depakote); epilepsy 600 mg/day (sodium valproate), titrated as needed; migraine prophylaxis (off-label) often 500 mg/day.

Off‑label NHS practice occasionally uses divalproex for neuropathic pain syndromes, augmentation in treatment‑resistant psychiatric conditions and specialist paediatric epilepsy regimens within tertiary centres.

NHS trust formularies and the UK valproate Pregnancy Prevention Programme set firm limits on use in women of childbearing potential, with mandatory documented counselling and contraception requirements.

Approved indications

Manic episodes in bipolar disorder (Depakote); epilepsy (other valproate products).

Typical NHS use

Refractory generalised epilepsy, acute mania requiring rapid mood stabilisation, migraine prophylaxis under neurologist care.

Monitoring requirements

Baseline and routine LFTs, full blood count/platelets, plasma valproate levels where indicated, and pregnancy testing in women of childbearing potential.

Paediatric use is common under specialist supervision but carries higher hepatic risk under three years of age and requires extra caution.

Composition and brand landscape — formulations, UK availability

People often want a quick list of what packs and brands look like in the UK market.

The active ingredient is valproate semisodium (divalproex sodium), a valproate derivative categorised under ATC code N03AG01 as a fatty‑acid anticonvulsant.

In the UK, Depakote is supplied as 250 mg and 500 mg gastro-resistant tablets; other valproate products are available as tablets, capsules and oral solution.

Depakote is made by Sanofi, and multiple generic manufacturers supply valproate tablets and oral solutions in the UK.

Contraindications and special precautions — high‑risk groups

People worry about who should never take Depakote and who needs extra checks.

Absolute contraindications listed in product data include known hypersensitivity to divalproex or related compounds, severe hepatic impairment, urea cycle disorders, known mitochondrial disorders such as Alpers‑Huttenlocher syndrome, and pregnancy (in bipolar disorder; in epilepsy unless there is no suitable alternative).

Relative contraindications that require close monitoring include coagulopathies due to risk of thrombocytopenia, a history of pancreatitis, renal impairment, elderly patients due to sedation and falls, and women of childbearing potential who must use reliable contraception.

• Absolute contraindications: hypersensitivity, severe liver disease, urea cycle disorders, known mitochondrial disorders, pregnancy (see above).
• Relative contraindications: coagulopathy, pancreatitis history, renal impairment, elderly patients, women of childbearing potential without effective contraception.

Special populations note: children under three years are at heightened hepatic risk and require specialist review and frequent monitoring.

Practical UK precautions include baseline and routine LFTs, full blood count with platelets, pregnancy testing where applicable, and advice about not driving if sedated.

Dosage guidelines — NHS standard regimens and adjustments

Patients ask for simple step‑by‑step titration and monitoring guidance.

For epilepsy, sodium valproate is usually started in adults at 600 mg daily in divided doses and titrated according to response, usually to 1,000–2,000 mg daily (20–30 mg/kg/day), with a maximum of 2,500 mg daily.

Bipolar mania often starts at around 750 mg/day in divided doses, while migraine prevention (off-label) commonly begins at 500 mg/day and is titrated to effect.

1. Step 1: Confirm indication, baseline bloods (LFTs, FBC/platelets), and pregnancy status where relevant.
2. Step 2: Start at the usual starting dose for the indication, as above.
3. Step 3: Review clinical response and consider measuring plasma valproate levels to guide titration.
4. Step 4: Maintain regular monitoring and adjust dose upward carefully to a maximum if required and tolerated.

Children, the elderly and those with hepatic impairment require lower starts or specialist dosing and closer review in line with NHS shared care arrangements.

Interactions overview — drugs and food

Patients commonly ask whether Depakote plays badly with other medicines or alcohol.

Divalproex has several clinically important interactions with enzyme‑modifying drugs and central nervous system depressants.

Co‑administration with other sedatives increases the risk of CNS depression, so caution is required with benzodiazepines and opioids.

Interactions with enzyme inducers or inhibitors can alter plasma valproate levels and affect efficacy and toxicity, so drug‑interaction checks are essential before starting new medicines.

Serious adverse events include hepatic failure, pancreatitis and thrombocytopenia, and suspected reactions should be reported via the MHRA Yellow Card scheme.

Checklist for patient counselling: avoid alcohol, check OTC medicines before use, report unexplained bruising or bleeding, and seek urgent advice for severe abdominal pain or jaundice.

Comparable medicines and prescribing preferences — pros and cons

Patients often ask which alternatives might work better than Depakote for them.

Common alternatives on NHS formularies include carbamazepine, lamotrigine, levetiracetam and topiramate, each with specific strengths and limitations.

Lamotrigine is often favoured for women of childbearing potential because of a lower teratogenic risk than valproate compounds.

Levetiracetam is popular for ease of titration and fewer drug interactions, while carbamazepine is useful for focal seizures but has a more complex interaction and hypersensitivity profile.

Shared decision‑making is integral to NHS prescribing, and documentation of pregnancy counselling is required for valproate prescriptions in women of childbearing potential.

FAQ — common NHS patient questions answered

1. Is valproate safe in pregnancy?
2. No; valproate and divalproex are associated with a high risk of major congenital malformations and neurodevelopmental disorders, and the MHRA mandates Pregnancy Prevention Programme measures.
3. Key PPP steps: documented counselling, effective contraception, pregnancy testing, clear record in notes.
4. What if I miss a dose?
5. Take the missed dose as soon as remembered unless the next dose is near, and never double up a dose.
6. Will I need blood tests?
7. Yes; baseline LFTs, full blood count/platelets and periodic monitoring are recommended, and therapeutic‑drug levels are commonly used in NHS follow‑up.
8. Can I drive or drink alcohol?
9. Driving is allowed if seizures are controlled and DVLA rules are met; avoid alcohol because of additive sedation and safety risks, and discuss any driving concerns with your clinician.

Guidelines for proper use — UK pharmacist counselling and NHS resources

Patients expect a clear checklist when collecting Depakote from a pharmacy.

Pharmacist counselling should cover the medicine name and formulation, dosing schedule, the importance of adherence, plasma level monitoring, and the need for baseline and routine blood tests.

Contraception and pregnancy risks must be discussed and documented in line with the UK valproate Pregnancy Prevention Programme before prescribing to women of childbearing potential.

Advice on driving and alcohol, how to report side effects to MHRA Yellow Card, and where to find reliable patient support (Epilepsy Action, Bipolar UK) should be provided.

Pharmacy actions

Provide patient leaflet, confirm recent blood tests, record PPP compliance where applicable, and offer structured medication review if concerns arise.

For urgent issues, advise use of NHS 111 and local trust portals for neurology or psychiatry appointments.

In our online pharmacy, Depakote is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Delivery across the United Kingdom